

Remedy Pharmaceuticals Begins Phase 1 Safety Study

Milestone study means commercializing life-saving drug for acute central nervous system disorders is a step closer

New York, NY, USA - January 25, 2010 – Remedy Pharmaceuticals, Inc. today announced that earlier this week the FDA completed its review of the Company's Investigational New Drug (IND) application and the Neurology division has decided that the proposed Phase 1 study titled "A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of RP-1127 in Healthy Male and Female Volunteers" may proceed. Enrollment of patients will begin immediately.

The study, designed to evaluate the safety and tolerability of different dose levels of RP-1127 administered as a bolus dose followed by a 3-day continuous infusion, will enroll volunteers at the Jasper Clinic in Kalamazoo, MI. Study subjects will be housed in the Jasper in-patient facility to allow for continuous safety monitoring.

"Administering RP-1127 to human patients in this Phase 1 safety study is an incredibly important milestone," said Sven Jacobson, Chief Executive Officer of Remedy. "This drug could help save lives and improve the quality of life for millions of people. We're one step closer to achieving that objective."

Detailed information for this study is available at:
<http://clinicaltrials.gov/ct2/show/NCT01132703>

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com